Developer docs
API playgroundTry for free, no card

Search company profiles

The Vertical Group

Full company profile

uuid00089rh

Namestring
The Vertical Group
Legal namestring
The Vertical Group, L.P.
Company typeenum
Private
Founded yearint
1988
Descriptiontext

The Vertical Group is a New Jersey-based venture capital firm founded in 1988 as the successor to the venture capital division of F. Eberstadt & Co., with a 40+ year exclusive focus on medical technology and biotechnology investments. The firm is structured as a limited partnership (The Vertical Group, L.P.) and manages at least two venture funds — Vertical Fund I, L.P. and Vertical Fund II, L.P. — deploying capital in ticket sizes ranging from $250,000 to $5,000,000 across seed, Series A, and later-stage rounds. Its four General Partners (Richard B. Emmitt, John E. Runnells, Jack W. Lasersohn, and Tony M. Chou, MD) collectively bring expertise spanning investment research, law, regulatory affairs, interventional cardiology, and medical device executive experience; partners hold board seats across the portfolio and, in Tony Chou's case, also serve as founder/CEO of Route 92 Medical.

The firm has generated several multi-billion-dollar exits from its portfolio, including Kyphon ($3.9B acquisition by Medtronic in 2007), ev3 ($2.6B by Covidien in 2010), Ventana Medical Systems ($3.9B by Roche), and Lifecell ($1.8B by KCI in 2008). The firm's go-to-market relies entirely on relationship-driven deal sourcing through the partners' network, NVCA involvement (the firm was among founders of the NVCA Medical Industry Group), and direct board-level engagement with portfolio companies. Revenue is generated through the standard VC fund model: recurring management fees on committed capital (typically 1.5–2% annually for the industry) plus carried interest on successful exits, with the firm headquartered in Basking Ridge, NJ and maintaining a second office in San Mateo, CA.

Short descriptiontext

The Vertical Group is a New Jersey-based venture capital firm focused exclusively on medical technology and biotechnology, deploying $250K–$5M checks across seed through later-stage rounds from Vertical Fund I and II.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerkeley Heights, United States
HQ citystring
Berkeley Heights
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, medical technology investments, biotechnology venture funding, healthcare private equity, medical device venture capital
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Healthcare and Biotechnology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management - Management Fees
TypeSubscription Recurring
Description

The firm manages venture capital funds (Vertical Fund I, L.P., Vertical Fund II, L.P.) and charges management fees on committed capital.

vertical-group.com
2Carried Interest
TypeTransaction Fee
Description

The firm earns carried interest (typically 20% of profits) from successful portfolio company exits, aligning GP and LP incentives.

vertical-group.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
Pricing details1 tier
1Investment size ranging from $250,000 to $5,000,000 per transaction
ModelOtherBilling cadenceMulti-year contract
Notes

The scale of The Vertical Group's investment depends on the nature of the transaction, with investment size ranging from $250,000 to $5,000,000 in various stages of angel and venture capital transactions.

vertical-group.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Vertical Group is a venture capital firm that invests in early-stage and later-stage medical technology and biotechnology companies, deploying between $250,000 and $5,000,000 per transaction through fund vehicles (Vertical Fund I, L.P. and Vertical Fund II, L.P.). Partners take board seats and contribute operating expertise in R&D, regulatory affairs, sales and marketing, and transaction structuring to support portfolio company growth and exits.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The Vertical Group is a venture capital firm, not a product company. It does not offer a unified platform or product suite. The firm provides investment services in the medical technology and biotechnology sectors, participating in venture financing rounds for portfolio companies. The firm's investment approach leverages the medical device industry knowledge and experience of its general partners.

Product and service1 record
1The Vertical Group Investment Services
CategoryVenture Capital Investment Management
Description

Venture capital investment services delivered through Limited Partnership funds (Vertical Fund I, L.P. and Vertical Fund II, L.P.), investing $250,000 to $5,000,000 per transaction in early-stage angel financings and early and later-stage venture capital financings of medical technology and biotechnology companies, with partners providing operating support in R&D, regulatory affairs, sales and marketing and transaction structuring.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-04
Description

Trace Medical signed a long-term distribution agreement with Outset Medical to rent the Tablo Hemodialysis System to HME providers. Trace Medical's national distribution platform serves approximately 30 million patients annually.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest healthcare-dedicated investment firms globally, covering medtech, biotech, and diagnostics across all stages. OrbiMed is the closest direct peer to The Vertical Group's specialist medtech/biotech focus, with overlapping exit sizes and co-investment profiles.

TypeDirect peer
Description

Healthcare-focused venture and growth firm investing across biopharma and medtech from seed through public stages. Frazier is highly comparable as a long-tenured, sector-specialist firm with similar fund structure and check-size ranges.

TypeDirect peer
Description

Healthcare-only venture firm investing in therapeutics, medical devices, and diagnostics. Domain's exclusive healthcare mandate and stage range closely mirror The Vertical Group's approach.

TypeDirect peer
Description

Venture and growth equity firm exclusively focused on life sciences, including medical devices and biotech. Comparable fund size, stage focus, and sector concentration to The Vertical Group.

TypeDirect peer
Description

Healthcare and medical technology-focused venture capital firm investing across medtech, biotech, and healthcare services. Sante Ventures is comparable as a sector-specialist with overlapping device and biotech portfolio themes.

TypeEmerging player
Description

Medical-device-focused private equity and venture firm investing in lower-middle-market healthcare technology companies. Comparable in its medtech-only thesis, though typically later-stage than The Vertical Group's seed/early focus.

TypeDirect peer
Description

Healthcare-only venture and growth firm with biotech and medtech strategies including a dedicated medical devices franchise. SV's sector specialization and stage breadth make it a strong comparability reference.

TypeEmerging player
Description

Mid-market healthcare growth equity practice investing in medical devices, healthcare services, and life sciences. Comparable as a healthcare-only investor with growth-stage medtech exposure.

TypeBroad incumbent
Description

Large multi-stage venture firm with a significant healthcare practice that has co-invested alongside The Vertical Group (e.g., Omada Health Series A). NEA is a broader incumbent, but its healthcare team competes head-to-head on medtech deals.

TypeBroad incumbent
Description

Global growth investor with a deep healthcare practice that has co-invested with The Vertical Group (e.g., Outset Medical, Tornier). Warburg is a broader incumbent but a frequent medtech co-investor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment74 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Vertical Group

Venture Capital (Healthcare and Biotechnology)vertical-group.com

The Vertical Group is a New Jersey-based venture capital firm focused exclusively on medical technology and biotechnology, deploying $250K–$5M checks across seed through later-stage rounds from Vertical Fund I and II.

What The Vertical Group does

The Vertical Group is a New Jersey-based venture capital firm founded in 1988 as the successor to the venture capital division of F. Eberstadt & Co., with a 40+ year exclusive focus on medical technology and biotechnology investments. The firm is structured as a limited partnership (The Vertical Group, L.P.) and manages at least two venture funds — Vertical Fund I, L.P. and Vertical Fund II, L.P. — deploying capital in ticket sizes ranging from $250,000 to $5,000,000 across seed, Series A, and later-stage rounds. Its four General Partners (Richard B. Emmitt, John E. Runnells, Jack W. Lasersohn, and Tony M. Chou, MD) collectively bring expertise spanning investment research, law, regulatory affairs, interventional cardiology, and medical device executive experience; partners hold board seats across the portfolio and, in Tony Chou's case, also serve as founder/CEO of Route 92 Medical.

The firm has generated several multi-billion-dollar exits from its portfolio, including Kyphon ($3.9B acquisition by Medtronic in 2007), ev3 ($2.6B by Covidien in 2010), Ventana Medical Systems ($3.9B by Roche), and Lifecell ($1.8B by KCI in 2008). The firm's go-to-market relies entirely on relationship-driven deal sourcing through the partners' network, NVCA involvement (the firm was among founders of the NVCA Medical Industry Group), and direct board-level engagement with portfolio companies. Revenue is generated through the standard VC fund model: recurring management fees on committed capital (typically 1.5–2% annually for the industry) plus carried interest on successful exits, with the firm headquartered in Basking Ridge, NJ and maintaining a second office in San Mateo, CA.

The Vertical Group firmographics

Firmographics
Name
The Vertical Group
Legal name
The Vertical Group, L.P.
Website
https://vertical-group.com
Company type
Private
Founded year
1988
Operating status
Operating
Headcount range
11–50 employees
Short description
The Vertical Group is a New Jersey-based venture capital firm focused exclusively on medical technology and biotechnology, deploying $250K–$5M checks across seed through later-stage rounds from Vertical Fund I and II.
Ownership category
akta.pro rank

The Vertical Group industry classification

Industry
Product category
Venture Capital (Healthcare and Biotechnology)
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital investing
  • Medical technology investments
  • Biotechnology venture funding
  • Healthcare private equity
  • Medical device venture capital

Where The Vertical Group is headquartered

Location

Headquarters

HQ city
Berkeley Heights
HQ country
United States
HQ region
North America

Offices3 records

Markets served

The Vertical Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Fund Management - Management Fees: The firm manages venture capital funds (Vertical Fund I, L.P., Vertical Fund II, L.P.) and charges management fees on committed capital.
  2. Carried Interest: The firm earns carried interest (typically 20% of profits) from successful portfolio company exits, aligning GP and LP incentives.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInvestment size ranging from $250,000 to $5,000,000 per transaction

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

The Vertical Group product offering

Product offering

Core offering

The Vertical Group is a venture capital firm that invests in early-stage and later-stage medical technology and biotechnology companies, deploying between $250,000 and $5,000,000 per transaction through fund vehicles (Vertical Fund I, L.P. and Vertical Fund II, L.P.). Partners take board seats and contribute operating expertise in R&D, regulatory affairs, sales and marketing, and transaction structuring to support portfolio company growth and exits.

Product overview

The Vertical Group is a venture capital firm, not a product company. It does not offer a unified platform or product suite. The firm provides investment services in the medical technology and biotechnology sectors, participating in venture financing rounds for portfolio companies. The firm's investment approach leverages the medical device industry knowledge and experience of its general partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Vertical Group Investment Services Venture capital investment services delivered through Limited Partnership funds (Vertical Fund I, L.P. and Vertical Fund II, L.P.), investing $250,000 to $5,000,000 per transaction in early-stage angel financings and early and later-stage venture capital financings of medical technology and biotechnology companies, with partners providing operating support in R&D, regulatory affairs, sales and marketing and transaction structuring.

Companies that use The Vertical Group

Customer profile

Segments2 records

Ideal customer profiles2 records

The Vertical Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

The Vertical Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Trace MedicalcoreChannel Partner/ Reseller/ Distributor · 4 October 2023Trace Medical signed a long-term distribution agreement with Outset Medical to rent the Tablo Hemodialysis System to HME providers. Trace Medical's national distribution platform serves approximately 30 million patients annually.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

The Vertical Group competitors and assessment

Company assessment

Direct peers

  • OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally, covering medtech, biotech, and diagnostics across all stages. OrbiMed is the closest direct peer to The Vertical Group's specialist medtech/biotech focus, with overlapping exit sizes and co-investment profiles.
  • Frazier Healthcare Partners: Healthcare-focused venture and growth firm investing across biopharma and medtech from seed through public stages. Frazier is highly comparable as a long-tenured, sector-specialist firm with similar fund structure and check-size ranges.
  • Domain Associates: Healthcare-only venture firm investing in therapeutics, medical devices, and diagnostics. Domain's exclusive healthcare mandate and stage range closely mirror The Vertical Group's approach.
  • Longitude Capital: Venture and growth equity firm exclusively focused on life sciences, including medical devices and biotech. Comparable fund size, stage focus, and sector concentration to The Vertical Group.
  • Sante Ventures: Healthcare and medical technology-focused venture capital firm investing across medtech, biotech, and healthcare services. Sante Ventures is comparable as a sector-specialist with overlapping device and biotech portfolio themes.
  • SV Health Investors: Healthcare-only venture and growth firm with biotech and medtech strategies including a dedicated medical devices franchise. SV's sector specialization and stage breadth make it a strong comparability reference.

Emerging players

  • Accelmed: Medical-device-focused private equity and venture firm investing in lower-middle-market healthcare technology companies. Comparable in its medtech-only thesis, though typically later-stage than The Vertical Group's seed/early focus.
  • Baird Capital (Healthcare): Mid-market healthcare growth equity practice investing in medical devices, healthcare services, and life sciences. Comparable as a healthcare-only investor with growth-stage medtech exposure.

Broad incumbents

  • NEA (New Enterprise Associates): Large multi-stage venture firm with a significant healthcare practice that has co-invested alongside The Vertical Group (e.g., Omada Health Series A). NEA is a broader incumbent, but its healthcare team competes head-to-head on medtech deals.
  • Warburg Pincus: Global growth investor with a deep healthcare practice that has co-invested with The Vertical Group (e.g., Outset Medical, Tornier). Warburg is a broader incumbent but a frequent medtech co-investor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

The Vertical Group social profiles

Digital presence

The Vertical Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Vertical Group leadership team

Management profile

Number of profiles

Profiles4 records

The Vertical Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Vertical Group M&A and investment

M&A and investment

M&A

Investments74 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Vertical Group

What does The Vertical Group do?

The Vertical Group is a venture capital firm that invests in early-stage and later-stage medical technology and biotechnology companies, deploying between $250,000 and $5,000,000 per transaction through fund vehicles (Vertical Fund I, L.P. and Vertical Fund II, L.P.). Partners take board seats and contribute operating expertise in R&D, regulatory affairs, sales and marketing, and transaction structuring to support portfolio company growth and exits.

Is The Vertical Group a public or private company?

The Vertical Group is a private company. It is classified as management employee owned and is currently operating.

When was The Vertical Group founded?

The Vertical Group was founded in 1988. It employs 11 to 50 people.

Where is The Vertical Group based?

The Vertical Group is headquartered in Berkeley Heights, United States, in the North America region.

How does The Vertical Group make money?

Two revenue lines are on record. Fund Management - Management Fees are the primary driver. The others are carried Interest.

Who are The Vertical Group's main competitors?

Direct peers on record are OrbiMed Advisors, Frazier Healthcare Partners, Domain Associates, Longitude Capital, Sante Ventures and SV Health Investors. Emerging players are Accelmed and Baird Capital (Healthcare). Broad incumbents are NEA (New Enterprise Associates) and Warburg Pincus.

Does The Vertical Group have an API?

No public API is recorded for The Vertical Group.

What industry is The Vertical Group in?

The Vertical Group's product category is Venture Capital (Healthcare and Biotechnology). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceReEmerge, Inc. Exits Stealth with Oversubscribed $37M Series A to Challenge the Limitations of Chronic Cognitive Impairment Caused by Brain InjuriesReEmerge, Inc. exited stealth after closing an oversubscribed $37M Series A led by U.S. Venture Partners and Santé. The funds will support a clinical study of its CNRT therapy for traumatic brain injury, enrolling up to 40 patients. The company aims to shift cognitive care from rehabilitation to restoration.Venture Capital Access OnlineReEmerge, Inc. Exits Stealth with Oversubscribed $37M Series A to Challenge the Limitations of Chronic Cognitive Impairment Caused by Brain InjuriesReEmerge, Inc. exited stealth after closing an oversubscribed $37M Series A led by U.S. Venture Partners and Santé. The funds will support a clinical study of its CNRT therapy for traumatic brain injury, enrolling up to 40 patients. The company aims to shift cognitive care from rehabilitation to restoration.FxnewsgroupFINRA fines, suspends trader for alleged rule violationsPeter M. Rosten agreed to a $25,000 fine and a four-month suspension from FINRA member firms for violating Rule 2010. He placed non-bona fide limit buy orders to create false demand while selling shares from his personal account, causing a net loss.TechbuzznewsRoute 92 Medical Secures $50 Million to Accelerate Global Growth in Stroke Treatment TechnologyRoute 92 Medical raised $50 million in growth financing led by Novo Holdings to expand its stroke treatment platform. The company will use the capital for global commercialization and clinical evidence, with its headquarters now in West Jordan, Utah. It plans to create over 100 jobs and scale production.Eyes On EyecareLuminopia raises $16M to support amblyopia binocular digital therapeuticLuminopia, a Cambridge, Massachusetts company founded at Harvard, raised $16 million in oversubscribed Series A financing led by U.S. Venture Partners, with Broadfin Advisors, ShangBay Capital and Vertical Group participating. The FDA De Novo-approved binocular amblyopia therapy, for children ages 4 to 7, uses VR headsets to modify content for each eye. The software is currently prescription-only via eyecare professionals.VC News DailyMicroTransponder Raises $53M in Series EMicroTransponder, a medical device company headquartered in Austin, Texas, closed an oversubscribed $53 million Series E funding round. The round was led by US Venture Partners with participation from returning investors GPG Ventures and Exceller Hunt Ventures, as well as new investors Osage University Partners, Action Potential Venture Capital, and The Vertical Group. The company stated that Vivistim, its first FDA-approved neuroplasticity-based medical device designed for patients with neurological conditions affecting sensory and motor function, represents its inaugural commercial product.FinSMEsMonteris Medical Secures $30M Series B Equity FinancingMonteris Medical secured approximately $30M in Series B equity financing, led by Birchview Capital with participation from The Vertical Group and BDC Capital Healthcare Fund. The funds will expand commercial and clinical programs for its NeuroBlate robotic neurosurgical system, and two new investors will join the board.